Clinical Trials

MyeloidOther hematologic neoplasm

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04279847 2026-04-01

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

210 enrolled

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

70 enrolled

Phase 4 Active not recruiting

Hypereosinophilic Syndrome

NCT02386800 2026-03-16

CINC424A2X01B Rollover Protocol

279 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04217356 2026-01-26

ALLO-BAT

Active not recruiting

90 enrolled

Phase 3 Active not recruiting

Bone Marrow Neoplasms, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

330 enrolled

Neoplasms, Primary Myelofibrosis

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 1/2 Active not recruiting

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT04817007 2025-09-10

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

216 enrolled

Primary Myelofibrosis

NCT05548062 2025-09-03

Prospero

Active not recruiting

242 enrolled

Polycythemia Vera

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

21 enrolled

Neoplasms, Primary Myelofibrosis

NCT02577926 2025-06-10

Ruxo-BEAT

207 enrolled

Polycythemia Vera, Thrombocythemia, Essential

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm